| Bioactivity | Gadoterate meglumine (Gd-DOTA; P-449) is a non-specific paramagnetic gadolinium complex used as a contrast enhancer in magnetic resonance imaging (MRI). Gadoterate meglumine paramagnetics in MRI can change the uniformity of the local magnetic field, resulting in a shorter relaxation time for neighboring protons. Gadoterate meglumine's gadoterate ions combine with the ligand DOTA (1,4,7, 10-Tetraazacyclododecane-N,N',N ",N "-tetraacetic acid) to form a stable complex. This stability helps prevent gadolinium ions from dissociating from the complex, thereby reducing potential toxicity. Gadoterate meglumine, as a contrast agent in MRI, is able to shorten the longitudinal relaxation time (T1) of tissue, resulting in a brighter signal in MRI images. Gadoterate meglumine can be used for the study of the central nervous system (such as the brain and spinal cord), abdominal, pelvic organs, breast, bone and joint imaging, angiography, and cardiac electrophysiology[1]. |
| CAS | 92943-93-6 |
| Formula | C23H42GdN5O13 |
| Molar Mass | 753.86 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Bourrinet P, et al. Cardiovascular safety of gadoterate meglumine (Gd-DOTA)[J]. Investigative radiology, 2007, 42(2): 63-77. |
Gadoterate meglumine
CAS: 92943-93-6 F: C23H42GdN5O13 W: 753.86
Gadoterate meglumine (Gd-DOTA; P-449) is a non-specific paramagnetic gadolinium complex used as a contrast enhancer in m
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.